The Week in Review: Medical Device and Big Pharma Milestones

Guangzhou Improve Medical Instruments Co. is scheduled to complete its $68 million IPO on Shenzhen’s ChiNext exchange; Novartis opened a $250 million technical R&D and API center in Suzhou; Biostar Pharma announced a $1.1 million medical equipment and nutrient acquisition; Pfizer and Peking University will jointly develop novel technologies for drug discovery; aTyr Pharma published research on the mechanism underlying its drug development; AlphaRx signed a long-term CMO agreement with Venturepharm; NiTi™ Surgical Solutions reported the first China use of its surgical closing ColonRing™ product; Cellonis Biotech used a novel technology based on stem cells to eliminate a glioma; and Pfizer will co-promote a diabetes drug in China for Takeda Pharma. More details... Stock Symbol: (NYSE: NVS) (OTCBB: BSPM) (NYSE: PFE) (OTCBB: ALRX)